Pendulum Therapeutics has expanded its Mayo Clinic collaboration into women’s health and dermatology. Read what this could mean for microbiome medicine.
Aviva Bio’s AVA‑291 receives FDA development feedback for women’s testosterone therapy. See what makes it safer and what happens next in clinical trials.
Indivumed GmbH and the Wilmot Cancer Institute at the University of Rochester Medical Center have expanded their collaboration to accelerate the development of patient-derived tumor models and AI-informed therapeutic discovery for solid tumors with high unmet clinical need. What this collaboration changes for the cancer model ecosystem The expansion of the Indivumed and University of
The rapid progress of artificial intelligence in medical imaging is creating fresh optimism among healthcare leaders seeking to close the persistent equity gap in breast cancer screening. The regulatory push by Lunit, a Seoul-based AI diagnostics firm, for its Lunit INSIGHT Risk model, which estimates a woman’s five-year breast cancer risk directly from mammogram images,
The landscape of metastatic breast cancer treatment is facing a fundamental rethink, with the oncology field laser-focused on one of its greatest clinical challenges: how to break immune resistance and stop metastatic spread. Despite a wave of checkpoint inhibitor approvals and initial enthusiasm, progress in metastatic breast cancer—especially for subtypes like triple-negative and HER2-positive disease—has
Why this collaboration marks a turning point for AI-driven breast cancer diagnostics The ECOG-ACRIN Cancer Research Group and Caris Life Sciences have released early findings from a large-scale collaboration aimed at transforming how recurrence risk is predicted in early-stage breast cancer. Presented at the 2025 San Antonio Breast Cancer Symposium, the joint effort has produced
Actinium Pharmaceuticals, Inc. has presented new preclinical data for its alpha-particle radiotherapy candidate ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting potent anti-tumor activity across hormone receptor–positive, triple-negative, and therapy-resistant breast cancer models. The findings suggest that ATNM-400 could become a differentiated treatment option for patients with tumors that have progressed after
Eli Lilly and Company has released updated Phase 3 EMBER-3 results for Inluriyo, also known as imlunestrant, its oral estrogen receptor antagonist, in patients with estrogen receptor-positive and human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. These new data, presented at the 2025 San Antonio Breast Cancer Symposium and published in Annals
IDEAYA Biosciences files IND for IDE574, a KAT6/7 inhibitor for breast and lung cancer. Learn how this new class may change epigenetic treatment strategies.